SCHEDULE: Point72 Exits Position in Relay Therapeutics

Point72 Asset Management and Steven A. Cohen have reported a 0% beneficial ownership stake in Relay Therapeutics, Inc.

Summary

• Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have filed an amendment to their Schedule 13G.
• The reporting persons now hold 0% of the common stock of Relay Therapeutics, Inc.
• The filing confirms the complete divestment of the previously held position as of March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a standard regulatory disclosure of an investment exit rather than a fundamental change in the company's business operations.

Positives

• The filing indicates a clean exit from the position, removing any potential overhang from this specific institutional holder.

Negatives

• The departure of a significant institutional investor like Point72 may be perceived by some market participants as a lack of confidence in the issuer's near-term prospects.

Risks

• The company is subject to the inherent risks of the biotechnology sector, including clinical trial outcomes and regulatory approval processes.

Future Outlook

No forward-looking guidance is provided as this is an ownership disclosure filing.

Industry Context

StockSavvy.ai notes that institutional divestment in mid-cap biotech firms is common as funds rebalance portfolios or rotate out of specific therapeutic areas. This exit does not necessarily reflect a change in the fundamental value of Relay Therapeutics but rather a strategic decision by the Point72 investment team.

Comparison to Industry Standards

• Institutional exits are standard practice in the biotech sector and do not deviate from typical portfolio management cycles.
• The filing follows standard SEC disclosure requirements for entities dropping below the 5% reporting threshold.

Stakeholder Impact

• Shareholders may note the exit of a major institutional investor, which could lead to short-term volatility in trading volume.

Next Steps

• No further action required by the reporting persons regarding this issuer.

Key Dates

Keywords

Relay Therapeutics, Point72, Steven A. Cohen, 13G, Divestment, Biotech, Institutional Ownership